Skip to main content

Home/ Dogs-to-Stars Enterprises/ Group items tagged DTSE

Rss Feed Group items tagged

dhtobey Tobey

University Physicians Healthcare - UPH Executive Bios - 0 views

  • Lawrence Aldrich President and Chief Executive Officer (CEO) Larry Aldrich is an attorney with over 25 years of proven leadership abilities in diverse business positions. As President and CEO he is responsible for various corporate departments at UPH, including Legal/Risk, Information Systems, Electronic Medical Records, Marketing/Business Development/Contracts Administration and Facilities. Prior to joining UPH, Larry was the founding Chief Operating Officer at The Critical Path Institute (C-Path), a non-profit medical research organization focused on improving the safety and efficacy of the drug development process through the U.S. Food and Drug Administration. He also served as the president and CEO of Tucson Newspapers. Larry received his law degree from Tulane Law School and his civil engineering degree from Georgia Institute of Technology.
    • dhtobey Tobey
       
      Aldrich is the former head of Tucson Ventures. Scott is arranging presentation after our presentation development call with Jeanine.
dhtobey Tobey

US NSF - Dear Colleague Letter: Small Business Innovation Research and Small Business T... - 1 views

  • The Directorate for Engineering’s Division of Industrial Innovation and Partnerships’ Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs invites all active SBIR/STTR Phase I grantees to participate in the Phase IB supplemental funding opportunity. Phase IB supplements to Phase I grantees are intended to foster partnerships between strategic partners and investors and the SBIR/STTR companies.
  • Through this supplemental program, small businesses will be able to effectively leverage funding and investment from interested outside parties on the technology funded in Phase I that could lead to successful commercial products and processes and at the same time provide some of the gap funding required to carry the grantees' effort from Phase I to Phase II.
  • The objective of the Phase IB option is to extend the R&D efforts beyond the current grant to meet the product/process/software requirements of a third party investor to accelerate the Phase I project to the commercialization stage and enhance the overall strength of the commercial potential of the subsequent Phase II project. The Phase IB option extends the Phase I grant for six months, and the combined Phase I and IB project will typically not exceed one year in duration for the SBIR grant and one and one half years for the STTR grant.
  •  
    SBIR Phase 1B awards in conjunction with venture firms targeting this space might be prime prospects for the DTSE Methodology and commercialization services. I wonder if there is an easy way to get a list of currently active SBIR Phase I projects?
  •  
    I think is what Bob mentioned as a good thing for the grants he is working on? .. . maybe he has list.. he seems focused on grants these days
1 - 2 of 2
Showing 20 items per page